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The pharmaco-economics of peri-operative beta-blocker and 
statin therapy in South Africa 
B M Biccard, J W Sear, P Foex 
We conducted a pharmaco-economic analysis of the 
prospective peri-operative studies of beta-blocker and statin 
administration for major elective non-cardiac surgery, using 
the Discovery Health claims costs for 2004. This analysis shows 
that acute peri-operative beta-blockade and statin therapy 
could result in a cost saving through a reduction in major peri-
operative cardiovascular complications in patients with an 
Postoperative cardiovascular complications occur 
predominantly as a result of either prolonged myocardial 
ischaemia or rupture of unstable coronary plaques.1 These 
pathophysiologies may be attenuated by both acute peri-
operative beta-blockade or statin therapyY 
In previously published pharmaco-economic analyses of 
peri-operative beta-blocker and statin studies, we have shown 
that these drugs are cost-effective within the framework of the 
British National Health System (NHS).3A 
Using the same methodology previously employed,3•4 
we have now conducted a pharmaco-economic analysis for 
the use of beta-blocker and statin therapy in high-risk non-
cardiac surgical patients using South African health care costs. 
Unfortunately, as there are no South African data available on 
peri-operative outcomes associated with acute peri-operative 
beta-blocker or statin therapy, we have continued to use the 
incidences reported in the American and European literature.5-15 
In this analysis, we have also considered the effect of the 
prevention of myocardial ischaemia with peri-operative beta-
blockers on late postoperative cardiovascular complications}6•17 
which was not considered in our previous analysis.3 
Methods 
Peri-operative beta-blocker therapy 
This pharmaco-economic analysis compared the total expected 
cost of treating surgical patients with 200 mg metoprolol 
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expected peri-operative major cardiovascular complication rate 
exceeding 10% following elective major non-cardiac surgery. 
The validity of these findings is dependent on whether the 
incidence of cardiovascular complications following major non-
cardiac surgery reported in the international literature is found 
to be similar in South Africa. 
5 Afr Med J 2006; 96:1199-1202. 
for 30 days versus placebo for 30 days peri-operatively and 
following elective surgery, as prescribed according to the 
POISE protocoJ.l8 We examined all the published prospective 
studies examining the utility of beta-blockers in the peri-
operative period, and where major peri- and postoperative 
cardiovascular complications have been reported.5-13 For 
these, we determined the overall incidences of all-cause 
mortality, non-fatal myocardial infarction and non-fatal 
cardiac arrest within 30 days of surgery in both the treated 
and control groups of these studies. In addition, we also 
noted the mortality reported in a subset of two of the studies 
at 2 years.16.17 Because all drugs have potential adverse side-
effects, we have attempted to determine the overall incidences 
of adverse cardiovascular outcomes potentially attributable 
to beta-blocker administration, including hypotension and 
bradycardia needing treatment, congestive heart failure, 
bronchospasm and cerebrovascular accident. 
Peri-operative statin therapy 
From the two prospective peri-operative statin studies in 
patients undergoing major vascular surgery,14•15 we similarly 
determined the overall incidences of cardiac and all-cause 
death, myocardial infarction, unstable angina and stroke 
in the treated and control groups reported as in-hospital 
complications from the study by Schouten et al.14 and up to 
6 months from the study by Durazzo et al.15 For this analysis 
we have assumed all patients to be on a therapeutic dose of 
atorvastatin (20 mg daily for 45 days) as per the protocol of 
Durazzo et a!.l5 We also considered the cost of monitoring for, 
and treating, the complications associated with statin therapy. 
These included pre-operative hepatic and creatine kinase 
screening tests and four postoperative tests.14 The incidence IIJlD 
of peri-operative adverse events associated with statins is 
unknown. However it is likely to be more frequent than 
that recorded in medical patients as common risk factors for 
adverse peri-operative cardiac events have often been exclusion 
criteria in the statin trials of medical patients.1 Indeed, in 
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surgical patients14 the incidence of a peri-operative creatine 
kinase level > 10 times the upper limit of normal was found to 
be 40 times more common than that reported in large medical 
trials. 1 We assumed therefore that rhabdomyolysis in surgical 
patients may also be 40 times more common than reported 
in medical patients, giving a predicted incidence of 1.3% in 
surgical patients.4 The incidence of elevated hepatic enzymes in 
the peri-operative period has been reported as 2%.15 
For both the beta-blocker and statin pharmaco-economic 
analyses, we constructed a monetary balance sheet based on 
the reported cardiovascular and adverse drug events for all 
the patients reported in these trials.5.15 All costs were derived 
from the Discovery Health claims costs for patients in the age 
band 61- 75 years for 2004.18 The mean or median ages of the 
patients reported in the beta-blocker studies range from 60 
to 76 years,5· 11•13 and the mean age of the patients in the peri-
operative statin study contributing nearly 91% of the patients 
to our analysis was 64 years.14 The average total cost for all 
the events recorded in these studies is listed in Table I. The 
pharmaco-economic analyses of peri-operative beta-blocker 
and statin therapy (taking into account drug acquisition 
costs, managing adverse drug events and the cost of treating 
cardiovascular complications) was carried out as in our 
previous papers.3A 
Results 
Peri-operative beta-blocker therapy 
The reported clinical outcomes data of the 11 high-risk 
surgical studies of peri-operative beta-blockers5-13•16•17 are 
presented in Table II. Acute peri-operative beta-blockade 
significantly decreased peri-operative myocardial infarction, 
late cardiovascular deaths and all postoperative deaths up to 2 
years. The number-needed-to-treat (NNT) to prevent one major 
peri-operative cardiovascular event with acute peri-operative 
beta-blocker therapy was 20; and for peri-operative death alone 
the NNT was 72. The NNT to prevent both peri-operative 
and postoperative deaths for up to 2 years is 25, although this 
calculation does not include nearly 76% of the patients (for 
whom there are no available data), and thus the actual NNT is 
probably considerably smaller. 5-7• 9•10•12•13 However, beta-blocked 
patients had significantly increased drug-associated adverse 
events in comparison to the controls. 
Applying the Discovery Health claims costs for 200419 (Table 
I) to the reported incidences of cardiovascular complications 
and potential adverse drug events (Table II), we can show 
that acute peri-operative beta-blocker therapy may potentially 
save R869 per patient through the reduction in cardiovascular 
complications (Table III). 
Peri-operative statin therapy 
The reported cardiovascular complications in the prospective 
studies of peri-operative statin therapy are shown in Table 
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Table l. Costs of peri-operative beta-blocker and statin 
therapy and major cardiovascular complications for 
patients in the age band 61 - 75 years during 200419 
Events recorded in this analysis 
Direct and indirect costs of beta-blocker therapy 
Cost of 200 m:g/ day metoprolol for 30 days 
Cost of adverse drug events 
Congestive heart failure 
Hypotension, drug or unspecified 
Bradycardia, unspecified 
COPD with acute exacerbation 
Cerebrovascular accident 
Direct a.nd indirect costs of statin therapy 
Cost of atorvastatin 20 mg for 45 days 
Lipid profile (2 episodes) 
AST, ALT; CK (5 episodes) 
Cost of drug~associated adverse events 
Acute renal failure 
Acute hepatitis/ acute liver failure 
Costs of peri-operative cardiovascular 
complications 
Sudden cardiac death 
Non-fatal cardiac arrest 





















COPD;:;:; chrOnic obstrudive Pulmonary diSease; AST:::: aspa_rtate transaminase; ALT:::. 
alaniil~ :transaminase; CK = creatine kinase.-
* Costs are presented in South African rands (ZAR). 
IV. Similarly, application of the Discovery Health claims costs 
for 200418 (Table I) show that statin therapy could potentially 
save R1 822 per patient treated, through a reduction in 
cardiovascular complications (Table V). 
Discussion 
Using South African health care costs, this pharmaco-economic 
analysis suggests that both peri-operative beta-blocker and 
statin therapy (in addition to improving cardiovascular 
outcome in appropriately selected high-risk elective surgical 
patients) may result in cost-minimisation. However, these 
findings are based on cardiovascular outcomes reported in the 
internationalliterature5-15 and not in South African patients. 
Hence, our findings will only be valid if the same rate of 
peri-operative cardiovascular complications were to be found 
in South African patients. There is evidence, however, that 
the incidence of coronary artery disease is rapidly increasing 
in South African ethnic groups previously considered to be 
at low risk for coronary events/0 while other specific ethnic 
groups in South Africa are already known to be at considerable 
cardiovascular risk including the South African Asian Indian 
population,21 black patients with a history of cerebrovascular 
disease and hypertension/9•22 and South Africans of European 
descent.20 
Table II. Reported cardiovascular complications and adverse events in the prospective studies of acute peri-operative beta-
blocker therapy in high-risk surgical patients5-13•16•17 
Cardiovascular complications 
Non-fatal cardiac arrest 
Non-fatal MI 
Death within 30 days of surgery (A) 
Death up to 2 years after hospital discharget (B) 
All deaths up to 2 years 
(C =A+ B) 
Adverse events 
Congestive heart failure 
Hypotension needing treatment 




MI =myocardial infarction; CVA =cerebrovascular accident. 
*p-values shown are calculated using a two-tailed Fisher exact test. 














Table III. Cost analysis of peri-operative beta-blocker therapy per patient* 

























Beta-blocker therapy No beta-blocker therapy 
Cost of peri-operative cardiovascular complications (A) 
Cost of adverse drug events (B) 
Cost of beta-blocker or placebo therapy (C) 
Total cost (D = A + B + C) 
Incremental cost of beta-blocker therapy (E = D with 
beta-blockers - D without beta-blockers) 










Table IV. Reported adverse events in the prospective studies of statin therapy in vascular surgical patients14·15 
Death 












Table v. Cost analysis of peri-operative statin therapy per patient* 
Cost of peri-operative cardiovascular complications (A) 
Cost of statin therapy (B) 
Total cost (C = A + B) 
Incremental cost of statin therapy (D = C with statins -A without statins) 
*Costs are presented in South African rands (ZAR). 
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No statin therapy 
N=805 
32 (4.0%) 
89 (11.1 %) 














No statin therapy 
9 236.24 
9 236.24 
How to identify patients likely to benefit from peri-
operative beta-blocker or stalin therapy 
Our findings suggest that beta-blockers are only potentially 
cost-effective for patients with an expected major 
cardiovascular complication rate exceeding 10% following 
major non-cardiac surgery. This is an important strategic point, 
as when all risk groups are included the cardioprotective 
efficacy of acute peri-operative beta-blockade is inconclusive.23 
Similarly, peri-operative statin therapy is only potentially cost-
effective for patients undergoing vascular surgery with an 
expected major cardiovascular complication rate of 15.4%. 
Minimising side-effects associated with peri-
operative beta-blocker therapy in high-risk surgical 
patients 
Administering beta-blockers to high-risk patients is associated 
with a significantly increased risk of associated adverse drug 
events (Table II). This may be partly due to overdosage, but 
also to a small group with significant ventricular-wall motion 
abnormality unresponsive to peri-operative beta-blockers.24 
The high incidence of major peri-operative cardiovascular 
events in the untreated patients (11 %) suggests that all these 
patients should routinely have further cardiac investigation 
prior to surgery. Identification of a subgroup of patients who 
require optimisation of ventricular function as opposed to beta-
blockade is important.24 
Comparing the cost of peri-operative beta-blocker 
and stalin therapy with accepted medical (or non-
surgical) indications 
The cost analyses summarised in Tables III and V show that 
the reduction in peri-operative cardiovascular events offsets 
the total additional cost of peri-operative beta-blocker or statin 
therapy. This compares favourably with secondary prevention 
in high-risk medical patients. We have calculated that the cost 
in the UK of preventing a death at 2 years with peri-operative 
beta-blockade is 33% of the cost of preventing the same event 
in a medical patient after myocardial infarction/5 and that the 
cost of preventing a peri-operative death with statin therapy 
is 72% of the cost of preventing the same complication in the 
highest risk cohort of the Health Protection Study (unpublished 
observations). 
From the available data in the literature, we have not been 
able to evaluate the effect of peri-operative statin therapy on 
llnPJ long-term cardiovascular outcomes, although it is likely that 
this therapy would also positively affect outcome.1 
Conclusions 
Acute peri-operative beta-blocker and statin therapy may be 
cost-effective in high-risk surgical patients undergoing major 
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non-cardiac surgery and vascular surgery respectively in South 
Africa. 
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